![Jing Jing Xu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jing Jing Xu
Direktor/Vorstandsmitglied bei Hua Medicine (Shanghai) Co., Ltd.
Profil
Jing Jing Xu has a current job as a Member-Supervisory Board at Hua Medicine (Shanghai) Co., Ltd.
Aktive Positionen von Jing Jing Xu
Unternehmen | Position | Beginn |
---|---|---|
Hua Medicine (Shanghai) Co., Ltd.
![]() Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Hua Medicine (Shanghai) Co., Ltd.
![]() Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |